275 related articles for article (PubMed ID: 32829467)
21. 2019 Novel Coronavirus Pandemic: What Do We Know?
Margallo LN; Diaz M; Lim PP
S D Med; 2020 Jun; 73(6):262-264. PubMed ID: 32580258
[TBL] [Abstract][Full Text] [Related]
22.
Siddiqui R; Khan NA
ACS Chem Neurosci; 2020 Aug; 11(16):2391-2392. PubMed ID: 32786329
[TBL] [Abstract][Full Text] [Related]
23. Immunological environment shifts during pregnancy may affect the risk of developing severe complications in COVID-19 patients.
Sarapultsev A; Sarapultsev P
Am J Reprod Immunol; 2020 Sep; 84(3):e13285. PubMed ID: 32516444
[No Abstract] [Full Text] [Related]
24. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
Liu J; Li S; Liu J; Liang B; Wang X; Wang H; Li W; Tong Q; Yi J; Zhao L; Xiong L; Guo C; Tian J; Luo J; Yao J; Pang R; Shen H; Peng C; Liu T; Zhang Q; Wu J; Xu L; Lu S; Wang B; Weng Z; Han C; Zhu H; Zhou R; Zhou H; Chen X; Ye P; Zhu B; Wang L; Zhou W; He S; He Y; Jie S; Wei P; Zhang J; Lu Y; Wang W; Zhang L; Li L; Zhou F; Wang J; Dittmer U; Lu M; Hu Y; Yang D; Zheng X
EBioMedicine; 2020 May; 55():102763. PubMed ID: 32361250
[TBL] [Abstract][Full Text] [Related]
26. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.
De Biasi S; Meschiari M; Gibellini L; Bellinazzi C; Borella R; Fidanza L; Gozzi L; Iannone A; Lo Tartaro D; Mattioli M; Paolini A; Menozzi M; Milić J; Franceschi G; Fantini R; Tonelli R; Sita M; Sarti M; Trenti T; Brugioni L; Cicchetti L; Facchinetti F; Pietrangelo A; Clini E; Girardis M; Guaraldi G; Mussini C; Cossarizza A
Nat Commun; 2020 Jul; 11(1):3434. PubMed ID: 32632085
[TBL] [Abstract][Full Text] [Related]
27. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
29. Type 3 hypersensitivity in COVID-19 vasculitis.
Roncati L; Ligabue G; Fabbiani L; Malagoli C; Gallo G; Lusenti B; Nasillo V; Manenti A; Maiorana A
Clin Immunol; 2020 Aug; 217():108487. PubMed ID: 32479986
[TBL] [Abstract][Full Text] [Related]
30. Cellular immune responses to covid-19.
Sewell HF; Agius RM; Stewart M; Kendrick D
BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031
[No Abstract] [Full Text] [Related]
31. The many faces of the anti-COVID immune response.
Vardhana SA; Wolchok JD
J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32353870
[TBL] [Abstract][Full Text] [Related]
32. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
33. The immune system and COVID-19: Friend or foe?
Yazdanpanah F; Hamblin MR; Rezaei N
Life Sci; 2020 Sep; 256():117900. PubMed ID: 32502542
[TBL] [Abstract][Full Text] [Related]
34. The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach.
Morris G; Bortolasci CC; Puri BK; Olive L; Marx W; O'Neil A; Athan E; Carvalho AF; Maes M; Walder K; Berk M
Life Sci; 2020 Oct; 258():118166. PubMed ID: 32739471
[TBL] [Abstract][Full Text] [Related]
35. Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome.
Caracciolo M; Macheda S; Labate D; Tescione M; La Scala S; Vadalà E; Squillaci R; D'Aleo F; Morabito A; Garreffa C; Marciano MC; Oliva EN
Front Immunol; 2020; 11():1942. PubMed ID: 32983123
[TBL] [Abstract][Full Text] [Related]
36. Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.
Wang W; Liu X; Wu S; Chen S; Li Y; Nong L; Lie P; Huang L; Cheng L; Lin Y; He J
J Infect Dis; 2020 Oct; 222(9):1444-1451. PubMed ID: 32601708
[TBL] [Abstract][Full Text] [Related]
37. SARS-CoV-2: a storm is raging.
Pedersen SF; Ho YC
J Clin Invest; 2020 May; 130(5):2202-2205. PubMed ID: 32217834
[TBL] [Abstract][Full Text] [Related]
38. COVID-19 and myocardial injury: is there a role for interleukin-1 inhibition?
Imazio M; Andreis A; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2020 Jul; 21(7):465-466. PubMed ID: 32487869
[No Abstract] [Full Text] [Related]
39. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
40. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
